Vividion Therapeutics

company

About

Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.

  • 101 - 250

Details

Last Funding Type
Series B
Last Funding Money Raised
$82M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active

Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$267M
Vividion Therapeutics has raised a total of $267M in funding over 2 rounds. Their latest funding was raised on Feb 24, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 24, 2021 Series C $135M 2 Detail
Apr 30, 2019 Series B $82M 2 Detail
Feb 2, 2017 Series A $50M 2 ARCH Venture Partners
Versant Ventures
Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Vividion Therapeutics is funded by 2 investors. ARCH Venture Partners and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series C
Versant Ventures Series C